Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

Y0001460

Acetylsalicylic acid for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Acetylsalicylic acid, 2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
2-(CH3CO2)C6H4CO2H
CAS Number:
50-78-2
Molecular Weight:
180.16
Beilstein:
779271
MDL number:
MFCD00002430
UNSPSC Code:
41116107
PubChem Substance ID:
329831434
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

aspirin

manufacturer/tradename

EDQM

mp

134-136 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

human ... PTGS1(5742) , PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Acetylsalicylic acid for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

482.0 °F

Flash Point(C)

250 °C

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yu-Chi Tung et al.
Medical care, 52(6), 519-527 (2014-05-03)
A volume-outcome relationship has been found for acute myocardial infarction (AMI); however, the mechanisms underlying the relationship remain unclear. In particular, it is not known whether processes of care are mediators of the volume-outcome relationship, that is, whether the mechanisms
Gideon Sahar et al.
The Journal of thoracic and cardiovascular surgery, 149(4), 1042-1050 (2015-04-25)
We compared the flow rates, reactivity, and morphology of the distal internal thoracic artery and its branches, the superior epigastric and musculophrenic arteries, to test their applicability as possible conduits in coronary artery bypass grafting surgeries. Skeletonized internal thoracic artery
Gwen M C Masclee et al.
Gastroenterology, 147(4), 784-792 (2014-06-18)
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin increases the risk of upper gastrointestinal bleeding (UGIB). Guidelines suggest avoiding certain drug combinations, yet little is known about the magnitude of their interactions. We estimated the risk of UGIB
Yasuo Ikeda et al.
JAMA, 312(23), 2510-2520 (2014-11-18)
Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to an aging population. To determine whether daily, low-dose aspirin reduces the incidence of cardiovascular events in older Japanese patients with multiple atherosclerotic risk factors. The
Sigrun Halvorsen et al.
Journal of the American College of Cardiology, 64(3), 319-327 (2014-07-19)
Although the use of oral anticoagulants (vitamin K antagonists) has been abandoned in primary cardiovascular prevention due to lack of a favorable benefit-to-risk ratio, the indications for aspirin use in this setting continue to be a source of major debate
View All Related Papers

Articles

HPLC Analysis of Pain Relievers on Ascentis® Express C18

Separation of Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder; Caffeine, meets USP testing specifications, anhydrous; Benzoic acid, meets USP testing specifications; Aspirin, meets USP testing specifications

Protocols

HPLC Analysis of Aspirin and Salicylic Acid on Ascentis® Express RP-Amide

Separation of Acetylsalicylic acid, analytical standard; Salicylic acid, BioXtra, ≥99.0%

HPLC Analysis of Salicylic Acid and Acetylsalicylic Acid (Aspirin) on Ascentis® Express OH5

Separation of Salicylic acid, meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (calc. to the dried substance); Acetylsalicylic acid, purum, ≥99.0% (HPLC)

HPLC Analysis of Benzoic Acid and Related Compounds on Ascentis® RP-Amide

Separation of 4-Hydroxybenzoic acid; Acetylsalicylic acid; Benzoic acid; Salicylic acid; Ethyl 4-hydroxybenzoate

HPLC Analysis of Benzoic Acid Derivatives on Ascentis® C18

HPLC Analysis of Benzoic Acid Derivatives on Ascentis® C18

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service